BridgeBio Pharma (BBIO) PT Raised to $95 at Cantor Fitzgerald
Tweet
Share
E-mailGet Alerts BBIO Hot Sheet
Price: $65.48 +2.50%
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
Cantor Fitzgerald analyst Josh Schimmer raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $95.00 (from $70.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
- Sony Financial Holdings (8729:JP) (SNYFY) PT Lowered to JPY180 at Nomura/Instinet
- BorgWarner (BWA) PT Raised to $95 at Wolfe Research, 'Bullish Takeaways from CEO Meetings'
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
